Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination … – Novavax Investor Relations

GAITHERSBURG, Md., April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at theWorld Vaccine Congress 2024(WVC) inWashington, DC,April 2 to 4, 2024.

New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant. Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).

Differencesobserved in immunoglobulin (IgG) subclass responses and Fc-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared.

Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.

Dr. Robert Walker, Chief Medical Officer, Novavax, will participate in a panel discussion on The Future of COVID-19 Vaccinations on April 3, exploring the benefits of developing broadly protective antigens or combination vaccines.

Novavax presentations during WVC:

Mallory, R

Safety and Immunogenicity of the Novavax XBB.1.5 SARS- CoV-2 Vaccine in Previously mRNA Vaccinated Participants

Oral Presentation

April 3, 2024

10:10am (EDT)

Kalkeri, R

Distinct Differences in IgG4 switch and Fc effector functions between mRNA and Novavax protein-based COVID Vaccination

Oral Presentation

April 3, 2024

10:25am (EDT)

Mallory, R

Update on Novavax influenza and COVID- influenza combination vaccine

Oral Presentation

April 3, 2024

2:40pm (EDT)

About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering,developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based inGaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.comand LinkedInfor more information.

Contacts: Investors Erika Schultz 240-268-2022 [emailprotected]

Media Ali Chartan 240-720-7804 [emailprotected]

SOURCE NOVAVAX, INC

Go here to read the rest:

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination ... - Novavax Investor Relations